Illumina secure five year, $17m FDA contract
date:Sep 22, 2012
conventional molecular typing tools lack the resolution for differentiating tightly linked bacterial isolates and provide limited genetic differentiation of certain strains such as Salmonella.

MiSeq is suited for screening bacterial pathogens due to its speed, simple workflow, high resolution, and accuracy, which enhance the ability to identify close related bacterial isolates, said Illumina.

6/6 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/07 19:44